Read by QxMD icon Read

reumatoid arthritis

Rosario García-Vicuña, María Auxiliadora Martín-Martínez, María Rosa Gonzalez-Crespo, Jesús Tornero-Molina, Antonio Fernández-Nebro, Francisco Javier Blanco-García, Ricardo Blanco-Alonso, Sara Marsal-Barril
To establish a set of recommendations for the management of patients diagnosed with rheumatoid arthritis (RA) who cannot be treated with methotrexate (MTX) due to contraindications, drug toxicity or lack of adherence, and to establish therapeutic strategies more effective and safer in these RA patients. A qualitative analysis of the scientific evidence available to June 2015. The 2-round Delphi technique of consensus was used to collect and establish expert opinion based on the participants' clinical experience when only low quality evidence was available...
May 2017: Reumatología Clinica
Isidoro González-Álvaro, Isabel Castrejón, Ana M Ortiz, Esther Toledano, Santos Castañeda, Alberto García-Vadillo, Loreto Carmona
OBJECTIVE: To estimate cut-off points and to establish response criteria for the Hospital Universitario La Princesa Index (HUPI) in patients with chronic polyarthritis. METHODS: Two cohorts, one of early arthritis (Princesa Early Arthritis Register Longitudinal [PEARL] study) and other of long-term rheumatoid arthritis (Estudio de la Morbilidad y Expresión Clínica de la Artritis Reumatoide [EMECAR]) including altogether 1200 patients were used to determine cut-off values for remission, and for low, moderate and high activity through receiver operating curve (ROC) analysis...
2016: PloS One
Marina Amaral de Ávila Machado, Cristiano Soares de Moura, Felipe Ferré, Sasha Bernatsky, Elham Rahme, Francisco de Assis Acurcio
OBJECTIVE: To evaluate treatment persistence in patients with rheumatoid arthritis and ankylosing spondylitis who started therapies with disease-modifying antirheumatic drugs (DMARD) and tumor necrosis factor blockers (anti-TNF drugs). METHODS: This retrospective cohort study from July 2008 to September 2013 evaluated therapy persistence, which is defined as the period between the start of treatment until it is discontinued, allowing for an interval of up to 30 days between the prescription end and the start of the next prescription...
August 22, 2016: Revista de Saúde Pública
Carlos Abud-Mendoza
No abstract text is available yet for this article.
July 2015: Reumatología Clinica
Patrick Verschueren, Diederik De Cock, Luk Corluy, Rik Joos, Christine Langenaken, Veerle Taelman, Frank Raeman, Isabelle Ravelingien, Klaas Vandevyvere, Jan Lenaerts, Elke Geens, Piet Geusens, Johan Vanhoof, Anne Durnez, Jan Remans, Bert Vander Cruyssen, Els Van Essche, An Sileghem, Griet De Brabanter, Johan Joly, Kristien Van der Elst, Sabrina Meyfroidt, Rene Westhovens
INTRODUCTION: Considering a lack of efficacy data in patients with early rheumatoid arthritis (eRA) presenting without classical markers of poor prognosis, we compared methotrexate (MTX) with or without step-down glucocorticoids in the CareRA trial. METHODS: Disease-modifying antirheumatic drug-naïve patients with eRA were stratified into a low-risk group based on prognostic markers that included non-erosiveness, anti-citrullinated protein antibodies and rheumatoid factor negativity and low disease activity (Disease Activity Score in 28 joints based on C-reactive protein (DAS28(CRP)) ≤3...
2015: Arthritis Research & Therapy
Linda A Rasch, Lilian H D van Tuyl, Willem F Lems, Maarten Boers
Treatment with initial high-dose prednisolone and a combination of methotrexate (MTX) and sulfasalazine (SSZ) according to the COBRA regimen (Dutch acronym for combinatietherapie bij reumatoide artritis, 'combination therapy for rheumatoid arthritis'), has repeatedly been demonstrated to be very effective in early rheumatoid arthritis (RA). COBRA combination therapy is superior to initial monotherapy of SSZ and MTX, is also associated with a good long-term outcome, is as safe as other treatment regimes, and performs as well as the combination of high-dose MTX and the tumor necrosis factor antagonist infliximab...
2015: Neuroimmunomodulation
Marieke M ter Wee, Debby den Uyl, Maarten Boers, Pit Kerstens, Mike Nurmohamed, Dirkjan van Schaardenburg, Alexandre E Voskuyl, Willem F Lems
BACKGROUND: Recently, we documented the likely non-inferiority of Combinatietherapie Bij Reumatoïde Artritis (COBRA)-light therapy (methotrexate increased to 25 mg/week with initial prednisolone 30 mg/day) compared with the original COBRA therapy (methotrexate 7.5 mg/week, sulfasalazine 2 g/day, with initial prednisolone 60 mg/day) after 26 weeks in patients with early active rheumatoid arthritis (RA). OBJECTIVE: To assess the non-inferiority of COBRA-light versus COBRA after 1 year in terms of disease activity (DAS44), functional outcome (Health Assessment Questionnaire (HAQ)) and radiographic progression (Sharp/van der Heijde score (SHS)), and to assess the effect of adding etanercept...
June 2015: Annals of the Rheumatic Diseases
L Heimans, M van den Broek, S le Cessie, B Siegerink, N Riyazi, K H Han, P J S M Kerstens, T W J Huizinga, W F Lems, C F Allaart
OBJECTIVE: To assess the association between high body mass index (BMI) and treatment response in recent-onset rheumatoid arthritis. METHODS: In the Behandelstrategieën voor Reumatoide Artritis (Treatment Strategies for Rheumatoid Arthritis) study, 508 patients were randomized to initial monotherapy or combination therapy with prednisone or infliximab (IFX). The response to Disease Activity Score (DAS) ≤2.4-steered treatment (first dose and after 1 year) was compared between patients with a BMI <25 kg/m(2) and ≥25 kg/m(2) , using relative risk (RR) regression analyses...
August 2013: Arthritis Care & Research
Fulvia Ceccarelli, Carlo Perricone, Francesco Trotta, Giovanna Cuomo, Raffaele Pellerito, Gianfilippo Bagnato, Fausto Salaffi, Roberto Caporali, Maurizio Cutolo, Mauro Galeazzi, Ugo Fiocco, Giovanni Lapadula, Stefano Bombardieri, Girolamo Bianchi, Roberto Gorla, Anna Rita Giardina, Gaia Gallo, Angela Maria Giardino, Guido Valesini
OBJECTIVES: To provide a survey of disease activity in patients treated with standard care in Italian clinical practice. METHODS: This was an observational prospective cohort study in patients with early, aggressive rheumatoid arthritis (RA; duration ≤2 years but ≥6 weeks; DAS28 >3.2) naïve to anti-tumour necrosis factor (TNF) therapy who were treated with disease-modifying anti-rheumatic drugs (DMARDs) and/or biologics according to standard practice at 15 Italian ARPA (Artrite Reumatoide Precoce Aggressiva) centres...
May 2013: Clinical and Experimental Rheumatology
Ana Filipa Mourão, João Eurico Fonseca, Helena Canhão, Maria José Santos, Alexandra Bernardo, Ana Cordeiro, Ana Rita Cravo, Ana Ribeiro, Ana Teixeira, Anabela Barcelos, Armando Malcata, Augusto Faustino, Cátia Duarte, Célia Ribeiro, Dolores Nour, Domingos Araújo, Elsa Sousa, Eva Mariz, Filipa Ramos, Filipe Vinagre, Francisco Simões Ventura, Graça Sequeira, Helena Santos, Jaime Cunha Branco, J A Gomes, J A Silva, João Ramos, Jorge Espírito Santo, José António Costa, J A Silva, José Saraiva Ribeiro, Luís Inês, Luís Miranda, Luzia Sampaio, Maria Lúcia Costa, Mário Rodrigues, Maria Carmo Afonso, Maria Inês Cunha, Maria João Saavedra, Mário Viana Queiroz, Maura Couto, Miguel Bernardes, Mónica Bogas, Patrícia Pinto, Paula Valente, Paulo Coelho, Pedro Abreu, Sara Cortes, Sofia Pimenta, Sofia Ramiro, Ricardo Figueira, Teresa Nóvoa
The authors review the practical aspects of biological therapy use for rheumatoid arthritis patients, commenting safety issues before and after treatment initiation and the best treatment strategies to optimize efficacy.
October 2011: Acta Reumatológica Portuguesa
Antonio Serrano Hernández
The immune response foreign antigens require a perfect coordination of cells that participate in its different phases. The objective of the response is the rapid destruction of the microorganisms with a minimum repercussion on self-cells and tissues. The regulation of this process is carried out fundamentally by T lymphocytes. There are two main types of coordinator cells: helper cells, what organize the initial immune response, and regulatory cells, what avoid immune attack against self and once the infection is controlled, disassemble the response...
April 2009: Reumatología Clinica
Daniel Xibillé-Friedmann, Victor Mondragón-Flores, César Horcasitas de la Rosa
INTRODUCTION: Rheumatoid arthritis (RA), an important cause of disability, affects 1% of the population. Early diagnosis and referral to a rheumatologist are positive prognostic factor but diagnosis in many cases is in the hands of primary care physicians (PCP). OBJECTIVE: To determine the criteria used by PCP for diagnosis of RA and referral of these patients to a rheumatologist; to evaluate how many cases can be classified as RA according to the ACR. METHODS: Retrospective study of 530 patients referred by PCP and seen as outpatients at a rheumatology clinic in 2002...
September 2006: Reumatología Clinica
M D Ruiz-Montesinos, B Hernández-Cruz, R Ariza-Ariza, L Carmona, J Ballina, F Navarro-Sarabia et al.
OBJECTIVE: To assess the annual costs of rheumatoid arthritis (RA) patients attended at rheumatology units in Spanish public hospitals. METHODS: A longitudinal, prospective, multicenter, observational, 1-year study was performed in the rheumatology units of randomly selected Spanish public hospitals. Randomly selected RA patients were included. The patients made four visits (at baseline and every 4 months). Resource use and costs were collected from patient diaries and structured questionnaires...
December 2005: Reumatología Clinica
M D Ruiz-Montesinos, B Hernández-Cruz, R Ariza-Ariza, L Carmona, J Ballina, F Navarro-Sarabia et al.
OBJECTIVE: To determine resource use over a 1-year period in patients with rheumatoid arthritis (RA) attended in rheumatology units in hospitals within the Spanish public health system. PATIENTS AND METHODS: An observational, longitudinal, prospective, multicenter, 1-year study was performed in randomly selected rheumatology units in hospitals of the Spanish public health system. Patients with RA were randomly selected in each hospital. Four visits (at baseline and every 4 months) were conducted by a rheumatologist not routinely involved in the care of the patient...
October 2005: Reumatología Clinica
D Gaudio, A Galassi, P Poppa, C Cattaneo
In Italy many hundreds of victims of both armies who fought WWI still attend to be recovered and, if possible, identified and given back to their relatives. This study has as its objective to carry out a correct recovery, anthropological analysis and possible identification of these soldiers. Our plan has been elaborated so that it may involve various experts of different disciplines (archeologists, historians, antropologists, but also genetists and entomologists). So far, in this research project, 35 recovered skeletons have been studied...
2009: Medicina Nei Secoli
João Eurico Fonseca, Helena Canhão, Paulo Reis, Maria José Santos, Jaime Branco, Alberto Quintal, Armando Malcata, Domingos Araújo, Francisco Ventura, Guilherme Figueiredo, José Canas da Silva, José Vaz Patto, Mário Viana de Queiroz, Rui André Santos, Adriano José Neto, Alves de de Matos, Ana Rodrigues, Ana Filipa Mourão, Ana Sofia Ribeiro, Ana Rita Cravo, Anabela Barcelos, Anabela Cardoso, António Vilar, Arecili Braña, Augusto Faustino, Candida Silva, Fátima Godinho, Inês Cunha, José António Costa, José António Melo Gomes, José António Araújo Pinto, J A Pereira da Silva, Luís Cunha Miranda, Luís Inês, Luís Maurício Santos, Margarida Cruz, Maria João Salvador, Maria Júlia Ferreira, Maria Rial, Miguel Bernardes, Mónica Bogas, Paula Araújo, Pedro Machado, Patrícia Pinto, Rui Gomes de Melo, Sara Cortes, Sérgio Alcino, Susana Capela
The authors present the revised version of the Portuguese Society of Rheumatology (SPR) guidelines for the treatment of rheumatoid arthritis (RA) with biological therapies. In these guidelines the criteria for introduction and maintenance of biological agents are discussed as well as the contraindications and procedures in the case of non-responders. Biological treatment should be considered in RA patients with a disease activity score 28 (DAS 28) superior to 3.2 despite treatment with 20mg/week of methotrexate (MTX) for at least 3 months or, if such treatment is not possible, after 6 months of other conventional disease modifying drug or combination therapy...
January 2010: Acta Reumatológica Portuguesa
João Eurico Fonseca, J A Canas Silva, Helena Canhão, Maria José Santos, Anabela Barcelos, Luis Inês, Maria Lucia Costa, Mário Rodrigues, Alexandra Bernardo, Ana Cordeiro, Ana Rita Cravo, Ana Ribeiro, Ana Teixeira, Armando Malcata, Augusto Faustino, Célia Ribeiro, Dolores Nour, Domingos Araújo, Elsa Sousa, Eva Mariz, Filipa Ramos, Filipe Vinagre, Francisco Simões Ventura, Graça Sequeira, Helena Santos, Jaime Cunha Branco, João Ramos, Jorge Espírito Santo, José António Costa, J A Pereira da Silva, Luis Miranda, Luzia Sampaio, Maria Carmo Afonso, Maria João Saavedra, Maria Inês Cunha, Mário Viana Queiroz, Maura Couto, Patrícia Pinto, Paula Valente, Pedro Abreu, Ricardo Ornelas Figueira, Sofia Ramiro, Teresa Nóvoa, Miguel Bernardes
No abstract text is available yet for this article.
April 2009: Acta Reumatológica Portuguesa
Loreto Massardo, María E Suárez-Almazor, Mario H Cardiel, Arnulfo Nava, Roger A Levy, Ieda Laurindo, Enrique R Soriano, Eduardo Acevedo-Vázquez, Alberto Millán, Carlos Pineda-Villaseñor, Claudio Galarza-Maldonado, Carlo V Caballero-Uribe, Rolando Espinosa-Morales, Bernardo A Pons-Estel
OBJECTIVE: A consensus meeting of representatives of 18 Latin-American and Caribbean countries gathered in Reñaca, Chile, for 2 days to identify problems and provide recommendations for the care of patients with rheumatoid arthritis (RA) in Latin America, a region where poverty and other health priorities make the efforts to provide effective and high quality care difficult. This report includes recommendations for health professionals, patients, and health authorities in Latin America, with an emphasis on education and therapeutic issues...
June 2009: Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases
Isidoro González-Alvaro, Miguel Angel Descalzo, Loreto Carmona
INTRODUCTION: The disease activity in patients with rheumatoid arthritis has improved during the past decade. The availability of new drugs and also a better assessment of the disease have been proposed to be responsible for this improvement. In the present work we estimate the effect of these factors on disease activity and function in patients with rheumatoid arthritis at the beginning of the new century. METHODS: The Estudio de la Morbilidad y Expresión Clínica de la Artritis Reumatoide (EMECAR) cohort was assembled in 2000 from the random sampling of rheumatoid arthritis patients registered in 34 centers...
2008: Arthritis Research & Therapy
E R Soriano, C Galarza-Maldonado, M H Cardiel, B A Pons-Estel, L Massardo, C V Caballero-Uribe, A F Achurra-Castillo, L A Barile-Fabris, J Chávez-Corrales, J F Díaz-Coto, M H Esteva-Spinetti, M Guibert-Toledano, F Irazoque Palazuelos, M W Keiserman, A V Lomonte, L M H Mota, C Pineda Villaseñor, G S Alarcón
No abstract text is available yet for this article.
July 2008: Rheumatology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"